I agree that this site is using cookies. You can find further informations here.
X
Becka, Michael
53  results:
Search for persons X
?
1

Effects of the chymase inhibitor fulacimstat in diabetic ki..:

Rossing, Peter ; Strand, Jorma ; Avogaro, Angelo...
Nephrology Dialysis Transplantation.  36 (2020)  12 - p. 2263-2273 , 2020
Link: https://doi.org/10.1093/..
 
?
2

Effects of the chymase inhibitor fulacimstat on adverse car..:

Duengen, Hans-Dirk ; Kim, Raymond J. ; Zahger, Doron...
American Heart Journal.  224 (2020)  - p. 129-137 , 2020
Link: https://doi.org/10.1016/..
 
?
3

Safety and Tolerability of the Chymase Inhibitor Fulacimsta..:

Düngen, Hans‐Dirk ; Kober, Lars ; Nodari, Savina...
Clinical Pharmacology in Drug Development.  8 (2018)  7 - p. 942-951 , 2018
Link: https://doi.org/10.1002/..
 
?
4

Exploratory evaluation of pharmacodynamics, pharmacokinetic..:

Kubitza, Dagmar ; Willmann, Stefan ; Becka, Michael...
Thrombosis Journal.  16 (2018)  1 - p. , 2018
Link: https://doi.org/10.1186/..
 
?
5

Pharmacokinetics, Safety, and Tolerability of the Novel Chy..:

Kanefendt, Friederike ; Thuß, Uwe ; Becka, Michael...
Clinical Pharmacology in Drug Development.  8 (2018)  4 - p. 467-479 , 2018
Link: https://doi.org/10.1002/..
 
?
6

Topical administration of regorafenib eye drops: phase I do..:

Zimmermann, Torsten ; Höchel, Joachim ; Becka, Michael...
British Journal of Clinical Pharmacology.  84 (2018)  5 - p. 865-875 , 2018
Link: https://doi.org/10.1111/..
 
?
7

Pharmacodynamics and pharmacokinetics during the transition..:

Kubitza, Dagmar ; Becka, Michael ; Mück, Wolfgang.
British Journal of Clinical Pharmacology.  78 (2014)  2 - p. 353-363 , 2014
Link: https://doi.org/10.1111/..
 
?
8

Open-label, randomized study of the effect of rivaroxaban w..:

Wolzt, Michael ; Gouya, Ghazaleh ; Kapiotis, Stylianos...
Thrombosis Research.  132 (2013)  2 - p. 240-247 , 2013
Link: https://doi.org/10.1016/..
 
?
9

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riv..:

Mueck, Wolfgang ; Stampfuss, Jan ; Kubitza, Dagmar.
Clinical Pharmacokinetics.  53 (2013)  1 - p. 1-16 , 2013
Link: https://doi.org/10.1007/..
 
?
10

Investigation of Pharmacodynamic and Pharmacokinetic Intera..:

Kubitza, Dagmar ; Becka, Michael ; Schwers, Stephan.
Clinical Pharmacology in Drug Development.  2 (2013)  3 - p. 270-277 , 2013
Link: https://doi.org/10.1002/..
 
?
11

Co‐administration of rivaroxaban with drugs that share its ..:

Mueck, Wolfgang ; Kubitza, Dagmar ; Becka, Michael
British Journal of Clinical Pharmacology.  76 (2013)  3 - p. 455-466 , 2013
Link: https://doi.org/10.1111/..
 
?
12

The Influence of Age and Gender on the Pharmacokinetics and..:

Kubitza, Dagmar ; Becka, Michael ; Roth, Angelika.
The Journal of Clinical Pharmacology.  53 (2013)  3 - p. 249-255 , 2013
Link: https://doi.org/10.1002/..
 
?
13

Effect of hepatic impairment on the pharmacokinetics and ph..:

Kubitza, Dagmar ; Roth, Angelika ; Becka, Michael...
British Journal of Clinical Pharmacology.  76 (2013)  1 - p. 89-98 , 2013
Link: https://doi.org/10.1111/..
 
?
14

The effect of food on the absorption and pharmacokinetics o..:

Stampfuss, Jan ; Kubitza, Dagmar ; Becka, Michael.
Int. Journal of Clinical Pharmacology and Therapeutics.  51 (2013)  7 - p. 549-561 , 2013
Link: https://doi.org/10.5414/..
 
?
15

Effect of Co-Administration of Rivaroxaban and Clopidogrel ..:

Kubitza, Dagmar ; Becka, Michael ; Mück, Wolfgang.
Pharmaceuticals.  5 (2012)  3 - p. 279-296 , 2012
Link: https://doi.org/10.3390/..
 
1-15